The regulation of the synthesis of PtdIns(4,5)P 2 is emerging as being as complex as we might expect from the multi-functional nature of this lipid. In the present chapter we focus on one aspect of inositide metabolism, which is the functions of the Type II PIPkins (Type II PtdInsP kinases). These are primarily PtdIns5P 4-kinases, although in vitro they will also phosphorylate PtdIns3P to PtdIns(3,4)P 2 . Thus they have three, not necessarily exclusive, functions: to make PtdIns(4,5)P 2 by a quantitatively minor route, to remove PtdIns5P and to make PtdIns(3,4)P 2 by a route that does not involve a Class I PtdIns 3-kinase. None of these three possible functions has yet been unambiguously proven or ruled out. Of the three isoforms, α and β are widely expressed, the IIα being predominantly cytosolic and the IIβ primarily nuclear. PIPkin IIγ has a much more restricted tissue expression pattern, and appears to be localized primarily to intracellular vesicles. Here we introduce in turn each of the three Type II PIPkins, and discuss what we know about their localization, their regulation and their function.
Type II PIPkins
Until 1997 it was assumed that all PIPkins catalysed the same PtdIns4P 5-kinase reaction, but Rameh et al. [2] turned that idea upside down when they showed that the Type II enzymes are in fact 4-kinases, with PtdIns5P being preferred over PtdIns3P see [12] for further data on specifi city). These observations raise the interesting issue that we still do not know for certain which of the (non-mutually exclusive) functions of Type II PIPkins is/are correct: (i) to synthesize PtdIns(4,5)P 2 by an alternative (minor) route; (ii) to remove (and thus regulate levels of) PtdIns5P; (iii) to synthesize PtdIns(3,4)P 2 by an alternative (minor) route that does not involve a Type I PtdIns 3-kinase. We shall consider each of these in turn.
(i) PtdIns(4,5)P 2 synthesis
Function (i) is an attractive one, given the wide range of functions that PtdIns(4,5)P 2 is known to fulfi l in different cellular locations [1] , compartmentalization of PtdIns(4,5)P 2 function could obviously be improved by a route involving a different substrate. However, as yet we have no direct evidence for this function, and it is relevant to add that it only makes sense to synthesize PtdIns(4,5)P 2 by this route if the PtdIns5P substrate is made by a PtdIns 5-kinase, or by a PtdIns(3,5)P 2 3-phosphatase [13] , and not by one of the PtdIns(4,5)P 2 -phosphatases recently described by Ungewickell et al. [14] ; this latter route would self-evidently create a futile cycle. The identity of a putative physiological PtdIns 5-kinase remains unclear (see [15] for references). One candidate is a Type I PIPkin acting as a PtdIns 5-kinase, as it can in vitro [5] , and this possibility gains some indirect veracity from the observation that the two Types of PIPkin (I and II) interact, probably directly, with each other [16] . A simple explanation for this could be that they effi ciently catalyse consecutive (ii) PtdIns5P regulation (and function) Function (ii), the regulation of PtdIns5P levels, is equally attractive, and has some evidence in its favour. For example, Gozani et al. [17] have used transfection of cells with Type IIβ PIPkin as a way of manipulating nuclear PtdIns5P levels, as have Pendaries et al. [18] to manipulate total cell PtdIns5P. It is interesting to compare these data with our own inability to detect changes in cellular PtdIns5P caused by transfection with either IIα or IIβ PIPkins [15] . These latter data, which we interpreted as questioning the degree to which Type II PIPkins might regulate cellular PtdIns5P [15] , used a mass assay on whole cell lipid extracts, and it may be that in vivo functional assays for PtdIns5P [17, 18] are a better way of addressing whether Type II PIPkins have physiological relevance as PtdIns5P regulators. It is important to add here that the identifi cation by Pagliarini et al. [19] of a PtdIns5P phosphatase does offer a reasonable alternative for regulating PtdIns5P levels by its removal.
PtdIns5P has recently been shown by Pendaries et al. [18] to play an important role in infection of cells by Shigella fl exneri, and their principal suggestion is that it activates Akt (protein kinase B) in a PtdIns 3-kinase-dependent fashion, via a presently unknown mechanism, involving the activation of a tyrosine kinase. As mentioned above, these authors [18] used transfection with PIPkin IIβ as one strategy to manipulate PtdIns5P and thus modulate Akt activation, so it is interesting that Pagliarini et al. [19] were unable to detect any effect on Akt caused by transfection of cells with their PtdIns5P 5-phosphatase. There is clearly much we do not understand about the regulation of PtdIns5P, and the extent to which Type II PIPkins contribute to it. Finally, Sbrissa et al. [20] have provided intriguing evidence for a connection with insulin signalling (compare also [21, 22] , discussed below), in that PtdIns5P may be involved with actin regulation and GLUT-4 (glucose transporter 4) translocation.
If PtdIns5P is to have a function, it must have protein effectors, and currently these remain unclear. PtdIns5P can act as a feed-forward regulator of PtdIns(3,5)P 2 hydrolysis by myotubularins [13] , and there are two promising nuclear candidates as effectors. One is the chromatin-associated protein ING2 ( [17] , and see above), and the other is the transcription factor, TFIIH [23] . Both proteins bind PtdIns3P with an affi nity similar to PtdIns5P, so it remains an open question as to whether either uses PtdIns5P as a physiological regulator. It is, however, worth reiterating in this context that PtdIns5P is present in the nucleus and goes through dramatic changes during the cell cycle [24] .
(iii) PtdIns(3,4)P 2 synthesis PtdIns3P is signifi cantly (around two orders of magnitude) less favoured as an in vitro substrate for Type IIα PIPkin compared with PtdIns5P [2, 12] , and indeed, it is on this specifi city that the mass assay we devised using Type IIα PIPkin [12] depends. But substrate presentation has enormous effects on the activity and specifi city of lipid-metabolizing enzymes, and it remains possible that the synthesis by a Type II PIPkin of PtdIns(3,4)P 2 from PtdIns3P is a physiologically relevant reaction. Moreover, the association between Type I and Type II PIPkins [16] (above) may suggest a function different from that discussed above [the synthesis of PtdIns(4,5)P 2 ]: combined with the evidence that in cells stressed by oxidation, synthesis of PtdIns(3,4,5)P 3 probably takes place by a Type I PIPkin phosphorylating PtdIns(3,4)P 2 [7] , this association could catalyse a closely coupled pathway (involving the two Types of PIPkin) from PtdIns3P to PtdIns(3,4,5)P 3 . As a potential counter argument to this, it should be noted that in the experiments of Halstead et al. [7] , simplistically one might expect PKD (protein kinase D, also known as PKCµ) to be activated by the oxidative stress [25] and, as discussed below, phosphorylation of Type II PIPkins by PKD should inhibit them, and thus decrease rather than increase this pathway.
PIPkin II␣
This was the fi rst PIPkin to be cloned [26, 27] , and is probably the best understood. The knockout mouse for PIPkin IIα has no obvious phenotype (J. Hurov, L. Rameh and L. Cantley, personal communication), but it is an ubiquitously expressed isoform. It is predominantly cytosolic [28] , though there is evidence that it may not always be so. Boronenkov et al. [29] suggested there might be some in the nucleus, and in our own study [28] , 5-10% of HeLa cells transfected with Type IIα PIPkin showed a clear nuclear localization. It is diffi cult to resolve this issue clearly by transfection and, in the absence of really reliable isoform-specifi c antibodies to detect the endogenous enzyme, approaching it by knock-in tags in DT40 cells (see below) might be a way forward.
Type IIα PIPkin is subject to regulation by phosphorylation. For example in platelets its catalytic activity is negatively regulated by phosphorylation [30] , and recently a likely candidate for at least a part of that regulation has been identifi ed as PKD [31] . PKD phosphorylates Thr 376 , which is located on the 'activation loop' [32] of all three isoforms of Type II PIPkin, and mutation of this to an aspartate residue in PIPkin IIα markedly inhibits the enzyme, without altering its substrate specifi city [31] . Phosphorylation of Type IIα PIPkin by PKD takes place in intact cells, and is increased during stress induced by H 2 O 2 [31] .
As mentioned above, when considering the possible involvement of Type II PIPkin PtdIns3P 4-kinase activity in the H 2 O 2 -induced PtdIns(3,4,5)P 3 synthesis pathway of Halstead et al. [7] , the likelihood that H 2 O 2 treatment would cause a PKD-induced decrease in Type II PIPkin activity makes this a less attractive possibility. However, if the Type I/Type II PIPkin asssociation is instead catalysing a route from PtdIns to PtdIns(4,5)P 2 via PtdIns5P (above), one might predict that stress-induced PKD activation would, by inhibiting the Type II PIPkin, lead to an accumulation of PtdIns5P. No such accumulation has been detected by whole-cell mass assay [15] , but it may nevertheless occur in a localized region. It is interesting to note that PKD has previously been found to associate with a Type II PtdIns 4-kinase and a Type I PIPkin [33] , and has also [34] . Altogether, the links between inositol lipid kinases and PKD suggest that we have much more to learn about the physiology of their interactions.
Finally, PIPkin IIα has been reported to be activated as a result of tyrosine phosphorylation in rod outer segments [35] . The activation is likely to be indirect, as there was no evidence that the PIPkin IIα itself was phosphorylated [35] , but the marked inhibitory effect on total Type II PIPkin activity of rod outer segment homogenates caused by some tyrosine kinase inhibitors possibly implies a profound level of regulation, at least in this tissue.
PIPkinII␤
This isoform was the second to be cloned, and was discovered through its association with the TNF-α (tumour necrosis factor-α) receptor [36] . Carricaburu et al. [21] showed that increasing PIPkin IIβ in cells which had a low endogenous expression resulted in a lower amount of PtdIns(3,4,5)P 3 induced by insulin simulation, a phenomenon they attributed to increased PtdIns(3,4,5)P 3 degradation rather than decreased synthesis. Consistent with these observations, the knockout mouse for this isoform [22] shows increased insulin sensitivity and reduced adiposity. The molecular link between a Type II PIPkin and PtdIns(3,4,5)P 3 degradation is not yet established, but these studies are superfi cially consistent with the work cited above on the possible actions of PtdIns5P, derived from PtdIns(4,5)P 2 via the S. fl exneri PtdIns(4,5)P 2 4-phosphatase [18] . Thus if PtdIns5P in some way decreases PtdIns(3,4,5)P 3 hydrolysis, and Type IIβ regulates PtdIns5P levels, all the studies in this paragraph have an appealing consistency.
Castellino and Chao [37] have reported an association of PIPkin IIβ with EGF (epidermal growth factor) receptors, and a link of PIPkin IIβ with oncogenesis has been suggested by Luoh et al. [38] . It is still unclear, however, how all of these various reports of PIPkin IIβ function tie in with its proposed nuclear localization. Using transfection with a GFP (green fl uorescent protein)-tagged protein, PIPkin IIβ was shown to be localized to the nucleus [28] by a nuclear localization signal that consisted of an α-helix (α-helix number 7 in the nomenclature of Rao et al. [32] ). The presence of this α-helix, unique to the β isoform of Type II PIPkins [28] , was absolutely required for the enzyme to be nuclear, and recently we have extended our understanding of this requirement by the serendipitous fi nding shown in Figure 1 . We discovered that one of our GFP-tagged PIPkin IIβ clones no longer showed a nuclear localization in HeLa cells, and sequencing this clone revealed that a single nucleotide mutation had taken place which had resulted in a M296T amino acid substitution, right in the middle of α-helix 7. This substitution is unlikely to disrupt signifi cantly the α-helical structure [39] , yet this single change was enough to negate the nuclear localization; mutating it back to the wild-type methionine residue restored the status quo (Figure 1 ). This demonstrates an exquisitely specifi c requirement for this methionine residue, presumably for a precise interaction with whatever chaperone protein is taking PIPkin IIβ to the nucleus [28] .
As discussed above, the substrate of Type IIβ PIPkin, PtdIns5P, is found in the nucleus and its mass levels change signifi cantly through the cell cycle [24] , and moreover, some convincing evidence for a nuclear function for PtdIns5P and for its possible regulation by Type IIβ PIPkin, has been published [17] . So an important question is: given the unambiguous (and unusual) nuclear localization sequence in PIPkin IIβ, plus the evidence for its interactions with cell surface receptors and its possible links with PtdIns(3,4,5)P 3 hydrolysis (above), how much of the enzyme actually exists in the cytoplasm? In the absence of a PIPkin IIβ-specifi c antibody, and given the inherent fl aws in acute transfection as a means to answer a quantitative question like that, we have begun to try to address this issue by using the power of the genetics of the chicken cell line, DT40. We have knocked a tag [40] into the gene of the DT40 PIPkin IIβ, as shown in Figure 2 (note that the amino acid sequence of the crucial α-helix 7 is completely conserved in the chicken gene). By tagging the endogenous protein in this way, we hope to clarify its localization under stimulated and resting conditions, and at various points of the cell cycle.
PIPkin II␥
The PIPkin IIγ isoform was cloned by Itoh et al. in 1998 [41] , who suggested a localization in the endoplasmic reticulum, and showed that the enzyme is subject to phosphorylation. Since then it has been largely ignored, probably because it has no activity when expressed in bacterial cells. Itoh et al. [41] showed that it did have some activity when immunoprecipitated out of eukaryotic cells, with a substrate specifi city consistent with a Type II PIPkin. Given its inactivity when expressed in bacteria it is unclear whether the activity found by Itoh et al. was due to some post-translational modifi cation of the enzyme, or due to heterodimerization with either the IIα or IIβ isoforms. It is interesting that the small loop close to the PtdIns5P binding site (the 'G-loop', between β-sheets 3 and 4, in the nomenclature of Rao et al. [32] ) is signifi cantly shorter in the IIγ isoform compared with the IIα or IIβ, so a post-translational modifi cation in this region, or a difference in how the substrate binds to the enzyme (in part dictated by the physicochemical nature of the substrate, long known to be a crucial feature of the activity of lipid-metabolizing enzymes, see e.g. [42, 43] ) may be important features in defi ning whether the PIPkin IIγ is truly active in vivo.
PIPkin IIγ has other features which distinguish it from the other two PIPkin II isoforms, and these are summarized here (J.H. Clarke and R.F. Irvine, Figure 2 Tagging of endogenous PIPkin II␤ in DT40 cells. A His-FLAG double tag was knocked into the genome of DT40 cells essentially as described by Mosedale et al. [40] . Wild-type cells (left) or tagged cells (right) were lysed, His-tagged proteins were pulled out with nickel beads, eluted with imidazole, and the eluates blotted with an anti-FLAG antibody. The cell lysates were also blotted with an anti-actin antibody as a control for equal protein loading. unpublished work). It is of more recent origin in terms of evolution, at least as judged by our ability to fi nd it only in vertebrate genomes. It also appears to have a very limited tissue distribution. Using a specifi c antibody we have discovered that it is found in some areas of the brain, notably the cerebellum (Purkinje cells in particular), hippocampus (especially pyramidal cells), and the olfactory bulb, with a particularly high level in mitral and trigeminal cells. It is also expressed in the brain stem and in spinal neurones. Perhaps the most striking aspect of its expression is that it is undetectable in all other organs we have so far explored, but very highly expressed in kidney. Within this organ it is confi ned largely to the epithelial cells lining the distal tubule, yet it is absent in several other organs with signifi cant epithelial cell content (liver, lung, muscle). We have explored this presence or absence in tissues by immunoprecipitation and Western blotting, and Figure 3 illustrates an interesting limitation of Western blotting cell lysates without prior immunoprecipitation. We were initially unable to detect PIPkin IIγ in mouse brain extracts (even though we knew it should be there from in situ and reverse transcriptase-PCR) despite increasing the amount of protein loaded on the gels. Figure 3 shows why this is: it illustrates how the other proteins present in a tissue lysate can completely mask PIPkin IIγ from detection, an experiment that provides a cautionary tale to all who assay a protein's presence simply by blotting.
The subcellular location of PIPkin IIγ is also different from the two other isoforms. In neurones and in the kidney it appears to be primarily localized to abundant vesicles, whose identity is not clear, but which we suspect are involved in the reversible transport of proteins to and from the plasma membrane. In the kidney, for example, the regulation of levels of transport proteins, such as aquaporins and sodium channels, in the plasma membrane is a central part of the function of the epithelium. Similarly there is an active traffi cking of vesicles up and down the dendritic trees of neurones such as Purkinje cells, which is a part of their adaptive responses, and the vesicular localization of this poorly understood PIPkin gives rise to a hope that it will shortly become less enigmatic than it has been since it was cloned.
Conclusions
The original discovery that the PIPkins form two distinct families with different properties [44] raised a number of questions about why this should be so. The discovery that the Type I and II PIPkins catalyse different reactions [2] deepened the mystery signifi cantly, most especially for the Type II enzymes: notwithstanding the possible alternative functions of Type I PIPkins [5] [6] [7] , their primary raison d'être is unequivocally to synthesize the cell's PtdIns(4,5)P 2 . In contrast, the primary function(s) of the Type II enzymes remains open, and the strikingly different tissue distribution and subcellular localization between the three isoforms tell us that we have a long way to go before we understand why they are there.
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